Exosome-mediated delivery of antisense oligonucleotides targeting -synuclein ameliorates the pathology in a mouse model of Parkinson's disease

Jiaolong Yang,Shilin Luo,Jichun Zhang,Ting Yu,Zhihui Fu,Yongfa Zheng,Ximing Xu,Chaoyang Liu,Mingxia Fan,Zhentao Zhang
DOI: https://doi.org/10.1016/j.nbd.2020.105218
IF: 7.046
2021-01-01
Neurobiology of Disease
Abstract:Parkinson's disease (PD) is the second most common neurodegenerative disease. Pathologically, PD is characterized by the formation of Lewy bodies (LBs) in the brain, which mainly comprises phosphorylated and aggregated alpha-synuclein (alpha-syn). The aberrant aggregation of alpha-syn is believed to play a key role in the pathogenesis of PD. While alpha-syn expression can be reduced by antisense oligonucleotides (ASOs), the challenge to deliver ASOs safely and effectively into the neurons remains unresolved. Here, we developed a safe and highly effective ASO delivery method by using exosomes. We first identified the ASO sequence that selectively reduced alpha-syn expression: ASO4. Exosome-mediated delivery of ASO4 (exo-ASO4) showed high cellular uptake and low toxicity in primary neuronal cultures. Exo-ASO4 also significantly attenuated alpha-syn aggregation induced by pre formed alpha-syn fibrils in vitro. Exo-ASO4 intracerebroventricular injection into the brains of alpha-syn A53T mice, a transgenic model of PD, significantly decreased the expression of alpha-syn and attenuated its aggregation. Furthermore, exo-ASO4 ameliorated the degeneration of dopaminergic neurons in these mice. Finally, the alpha-syn A53T mice showed significantly improved locomotor functions after exo-ASO4 injection. Overall, this study demonstrates that exosome-mediated ASO4 delivery may be an effective treatment option for PD.
What problem does this paper attempt to address?